The usefulness of epirubicin in the treatment of adult and childhood malignant diseases is related in part to the potential reduction in cardiac toxicity compared with that of other anthracyclines given at equivalent doses. An important pathway for epirubicin detoxification is UGT2B7-dependent glucuronidation. This study was implemented to provide a preclinical evaluation of the metabolism of epirubicin with respect to age-related changes in epirubicin glucuronidation in pediatric liver microsomes. Rates of epirubicin glucuronidation and levels of UGT2B7 were determined for liver microsomes from four pediatric age categories (n ‫؍‬ 32) and one adult age category (n ‫؍‬ 8). Both sets of data showed an increase in UGT2B7 activity and content with increasing age. Epirubicin glucuronidation activity in the adult group was statistically higher compared with all pediatric age groups (p < 0.01). UGT2B7 expression also was statistically higher in adults compared with children below 11 years of age, with evidence of significant differences in protein levels among the pediatric age categories. A positive correlation (r ‫؍‬ 0.68) between UGT2B7 levels and postnatal age was observed, suggesting a progressive increase in UGT2B7 protein expression with increasing age. However, allometric scaling using the 3 ⁄4 power rule suggested no difference in activity between any of the pediatric age categories and the adult, although only a single neonatal sample was included in the analysis. In summary, these in vitro data show differences in epirubicin glucuronidation and UGT2B7 content within pediatric age groups and support the use of epirubicin in pediatric patients at least 6 months of age.
The anthracycline class of compounds has been used extensively as effective chemotherapeutic agents for a variety of hematological and solid tumors. Anthracyclines are known to be successful in the treatment of childhood-related malignancies, doxorubicin being used most frequently (Kremer et al., 2002; Katzenstein et al., 2003) . However, the potential myocardial toxicity associated with the cumulative dose of this drug is a major limitation for safe and effective pediatric use. Epirubicin or 4Ј-epi-doxorubicin, a synthetic derivative of daunorubicin, is a cell cycle phase, nonspecific anthracycline and has been used as a major component of cancer chemotherapy for a wide spectrum of metastatic diseases, including breast and bladder cancer (Ormrod et al., 1999; Lunardi et al., 2002; Harris et al., 2003) . The precise mechanism underlying epirubicin cytotoxicity has not been completely elucidated, and safety and efficacy have not been determined in pediatric patients.
Epirubicin and doxorubicin are structurally highly similar, differing only in the orientation of the 4Ј-hydroxy group. However, this minor difference leads to significant differences in the pharmacokinetics and metabolism of these drugs. Epirubicin is extensively metabolized by the liver to epirubicin glucuronide ( Fig. 1 ) and epirubicinol, with subsequent biliary excretion of the glucuronide conjugate (approximately 25% of dose) (Weenen et al., 1983 (Weenen et al., , 1984 . Using adult human liver microsomes and heterologous enzyme expression systems, this route of epirubicin inactivation was shown by Innocenti et al. (2001) to be catalyzed by UDPglucuronosyltransferase 2B7 (UGT2B7). Doxorubicin does not share this important detoxification pathway, thus suggesting that epirubicin represents an effective anthracycline possessing a favorable pharmacokinetic profile and fewer toxicological effects (Launchbury and Habboubi, 1993; Robert, 1993) . Clinical pharmacokinetic studies have demonstrated an up to 10-fold interpatient variability in epirubicin glucuronidation linked with metabolic clearance, and in vitro metabolism studies have provided evidence that interindividual variability in rates of glucuronidation seems related to variability in UGT2B7 protein levels. For example, the pharmacokinetics of morphine glucuronidation suggest both age-dependent differences in UGT2B7 activity and significant increases in enzyme expression and/or activity at birth. Adjusting for liver size relative to body weight, adult levels of UGT2B7 are reached by 2 to 6 months of age (reviewed in de Wildt et al., 1999) . Thus, the developmental pattern for this UGT isoform may provide valuable clinical information in the assessment of epirubicin pediatric pharmacology.
The objective of this study was to conduct a preclinical evaluation of the effect of age on UGT2B7-dependent epirubicin glucuronidation to support a clinical efficacy study in pediatric patients. Using a unique set of pediatric hepatic microsome samples and defined age categories, rates of epirubicin glucuronidation and immunodetectable levels of UGT2B7 were measured and each was analyzed for agedependent change.
Materials and Methods
Chemical and Reagents. Primary antisera containing an anti-peptide antibody against UGT2B7 and horseradish peroxidase-conjugated goat anti-rabbit antibody were obtained from BD Biosciences (Bedford, MA). Ten percent polyacrylamide Tris-HCl (1.0 mm Criterion) resolving gels and polyvinylidene difluoride transfer membranes (Immun-Blot) were obtained from Bio-Rad Laboratories (Hercules, CA). Premixed 10ϫ Tris/glycine/SDS running buffer, 10ϫ Tris/glycine transfer buffer, and Tween 20 also were obtained from Bio-Rad Laboratories. Sample buffers and reducing agents (NuPAGE) were obtained from Invitrogen (Carlsbad, CA). Enhanced chemiluminescence (ECL) blotting reagents and detection film (Hyperfilm ECL) were obtained from GE Healthcare (Little Chalfont, Buckinghamshire, UK). Tris-buffered saline buffer (BupH Tris-buffered saline) was purchased from Pierce Chemical Company (Rockford, IL). Epirubicin HCl and alamethicin were obtained from Pharmacia (Nerviano, Italy and Kalamazoo, MI, respectively). Daunorubicin, ␤-glucuronidase, and UDP-glucuronic acid (UDPGA) were obtained from Sigma-Aldrich (St. Louis, MO). All other reagents and materials were obtained from common commercial sources at the highest grade available.
Microsomes. Pediatric liver samples were obtained and microsome fractions prepared as described previously (Koukouritaki et al., 2002) . The age categories for the donor liver microsome samples are given in Table 1 . Pooled human liver microsomes were obtained from Xenotech LLC (Kansas City, KS) and individual adult liver microsomes were obtained from the Pfizer/Pharmacia liver microsome bank. Microsomes from insect cells infected with baculovirus expressing recombinant UGT2B7 were obtained from BD Biosciences Discovery Labware (Bedford, MA).
Epirubicin Glucuronidation Assay. Kinetic reactions with expressed UGT2B7 and pooled human liver microsomes were performed using a 100-l reaction mixture containing 0.5 mg/ml microsomal protein, 5.0 mM UDPGA, and 25 to 1200 M epirubicin in 50 mM Tris-HCl/8 mM MgCl 2 (pH 7.5) buffer containing alamethicin (50 g/mg protein) and incubated in a shaking water bath at 37°C for 15 min. Reactions with pediatric and adult liver microsomes were performed using 500 M epirubicin, 0.2 mg/ml protein, and 30-min incubation times under the same conditions described above. Chilled samples were preincubated at 37°C for 3 min and all reactions were initiated with the addition of 5 mM UDPGA to the reaction mixture. The reaction was terminated by the addition of 25 l of ice-cold acetonitrile/0.03% phosphoric acid containing 100 M daunorubicin as the internal standard and centrifuged at 10,000g for 3 min. A 50-l aliquot of the supernatant was used for high-performance liquid chromatography analysis. Preliminary experiments showed the glucuronidation assay was linear under conditions of a 30-min incubation and 0.5 mg of microsomal protein.
Epirubicin, epirubicin glucuronide, and daunorubicin were detected using a PerkinElmer Series 200 high-performance liquid chromatography system (PerkinElmer, Wellesley, MA) with fluorescence detection at 480 ( ex ) and 560 ( em ) nm using a Waters 474 fluorescence scanning detector (Waters Corp., Milford, MA). Separation was accomplished at room temperature using a reversed phase Supelcosil LC-CN column (4.6 ϫ 250 mm, 5 m; Supelco Inc., Bellefonte, PA) preceded by a SecurityGuard phenyl guard cartridge (Phenomenex, Torrance, CA) and a mobile phase consisting of 30% acetonitrile and 70% 50 mM sodium dihydrogen phosphate (pH 4.0) at a flow rate of 0.8 ml/min. The quantitation of the epirubicin glucuronide metabolite was performed by comparing chromatographic peak heights to a standard curve of 0.5 to 50.0 nmol epirubicin/ml constructed, because of the unavailability of pure epirubicin glucuronide. The assumption that the fluorescence of epirubicin glucuronide was equal to that of epirubicin is based on the comparative fluorescence spectra and has been used in related studies (Barker et al., 1996) . Identification of the epirubicin glucuronide chromatographic peak by enzymatic hydrolysis with ␤-glucuronidase was performed by treatment of a human liver microsome incubation sample with 1000 IU of ␤-glucuronidase (type VII, from Escherichia coli) in 0.1 M sodium phosphate buffer, pH 6.8 at 37°C overnight and analyzed as described above.
Electrophoresis and Immunoblotting. Proteins were separated by SDSpolyacrylamide gel electrophoresis using 10% acrylamide resolving gels and a Tris-glycine running buffer (Laemmli1970). A 2-to 3-g aliquot of microsomal protein from each sample was analyzed. Separation was carried out using the Criterion Precast Gel Electrophoresis System (Bio-Rad Laboratories) and proteins were transferred to polyvinylidene difluoride membranes using the Criterion blotter according to the manufacturer's instructions. Membranes were blocked with 5% nonfat dry milk (NFDM) in Tris-buffered saline (TBS; 25 mM Tris, 150 mM sodium chloride, pH 7.5). The transfer membranes were incubated for 1 h at room temperature with UGT2B7 primary antibody diluted 1:500 in TBS containing 1% NFDM and 0.05% Tween 20. The membranes were then washed several times with TBS containing 0.1% Tween 20 and incubated for 1 h at room temperature with the horseradish peroxidase-labeled secondary antibody diluted 1:500 in TBS containing 1% NFDM and 0.05% Tween 20. Membranes were then washed several times with TBS containing 0.1% Tween 20 and processed for UGT2B7 detection by enhanced chemiluminescence according to the manufacturer's instructions. The luminescence produced was detected by exposure to film and scanned using a Bio-Rad GS-710 calibrated imaging densitometer. Using a standard curve representing 0.01 to 0.25 g of expressed human UGT2B7 distributed on each membrane, immunoreactive protein bands were quantified using linear regression (Quantity One software; Bio-Rad Laboratories).
Statistical Analysis. Data from rates of epirubicin glucuronidation and UGT2B7 protein levels were analyzed with the statistical analysis package Unistat V5.0 (Unistat, London UK). These data were analyzed by the KruskalWallis nonparametric analysis of variance (Hollander and Wolfe, 1999) . Multiple comparisons were made using the t distribution on the mean ranks. Correlation analysis was performed using GraphPad Prism V3.0 (GraphPad Software Inc., San Diego CA). Epirubicin glucuronidation activities that were normalized by scaling to a 70-kg individual using the 3 ⁄4 power rule (Holford, 1996) were compared using one-way analysis of variance (SigmaStat V 3.11; SysStat Software, Point Richmond, CA). An ␣ value of p Ͻ 0.05 was accepted as significant.
Results
Kinetic Analysis of Epirubicin Glucuronidation. A description of incubation conditions and kinetic parameters for epirubicin glucuronidation has been reported (Innocenti et al., 2001) ; however, the limiting quantities of each sample for the current study necessitated incubations using substantially reduced concentrations of microsomal protein. In brief, under conditions of saturating substrate, less than 4% of the parent compound was consumed using lower protein concentrations (incubations of human liver microsome samples at 0.2 mg at ASPET Journals on July 7, 2017 dmd.aspetjournals.org protein/ml or 20 g of total protein and expressed UGT2B7 at 0.5 mg/ml or 50 g of total protein) for the respective incubation durations. Kinetic evaluations of epirubicin glucuronidation were performed using the above conditions with increasing concentrations of substrate. The resulting activities were fit to a single enzyme model (r 2 ϭ 0.9936) (data not shown). For a pooled adult human liver microsome sample, apparent K m (K m,app ) and maximal reaction rate (V max ) were 213 M and 3.56 nmol epirubicin glucuronide formed/ min/mg protein. For expressed UGT2B7, the calculated K m was 46 M with a V max of 0.86 nmol/min/mg protein.
Age-Dependent Differences in Epirubicin Glucuronidation. The rate of epirubicin glucuronidation was evaluated for four pediatric categories and one adult age category, each consisting of eight samples. Due to the limited number of available samples, categories were determined a priori to include this balanced observation approach, rather than by regression tree analysis and node identification. Figure  2 shows the box and whisker plot for epirubicin glucuronidation by age category. The statistical analysis showed no strong difference between mean rank values among the four pediatric age categories ( p Ͼ 0.05, Table 2) except the 12-to 17-year age category, which was different from the Ͻ1-year category ( p ϭ 0.02). Rates of epirubicin glucuronidation for pediatric samples showed high intersubject variability, particularly within the 6-to 11-year and 12-to 17-year categories. The adult category was characterized by lower interindividual variability (3-fold) and a high average activity (2.1 nmol/min/ mg) that was statistically different from each of the pediatric categories ( p Յ 0.05).
Immunoquantitation of UGT2B7 Protein. Since previous studies have identified UGT2B7 as the primary catalyst of epirubicin glucuronidation, the ontogeny of UGT2B7 expression was investigated. Figure 3 shows that a 25-fold dynamic range of UGT2B7 immunoquantitation could be obtained using the expressed enzyme, since detection of the 0.005-g sample was not reliable (Fig. 3, lanes 1-6) . An immunoreactive protein of molecular weight similar to that of expressed UGT2B7 was observed for six of eight samples from the Ͻ1-year pediatric category (Fig. 3, lanes 8 -15) and from all other human liver microsome samples analyzed (data not shown). Figure 4 shows the box and whisker plots for human liver microsome UGT2B7 protein levels by age category. The results follow a pattern similar to that observed for rates of epirubicin glucuronidation by age category in that a statistical difference was observed between the adult group compared with each of the pediatric groups except 12 to 17 years. The latter approached significance ( p ϭ 0.057). Average levels of UGT2B7 protein showed an age-dependent increase, and the differences in the pediatric age groups were significant for the 12-to 17-year age group compared with the Ͻ1-and 1-to 5-year age groups ( p Ͻ 0.001). The 6-to 11-year age group also showed a statistical difference compared with the Ͻ1-year age ( p Ͻ 0.001) and the 1-to 5-year group ( p ϭ 0.0086).
Correlation Analysis. A useful approach for reaction phenotype analysis of cytochrome P450-dependent processes is the correlation of marker enzyme activities with immunodetectable protein levels within a defined set of liver microsome samples (Parkinson 1996) . Therefore, this approach was applied to compare UGT2B7 protein levels with rates of epirubicin glucuronidation for all human liver microsome samples analyzed (Fig. 5) . These two parameters were significantly correlated (r ϭ 0.86, p Ͻ 0.001), thus further implicating UGT2B7 as the primary catalyst in epirubicin glucuronidation. Each of these parameters was then independently analyzed versus the postnatal age of the human liver sample donor. Figure 6A shows the rates of epirubicin glucuronidation with increasing postnatal age for the pediatric liver microsome samples. These variables showed a weak but significant correlation (r ϭ 0.36, p Ͻ 0.05). A similar analysis of liver microsomal UGT2B7 levels versus postnatal age showed a stronger correlation (r ϭ 0.68, p Ͻ 0.001) (Fig. 6B) . Together, these results suggest an age-dependent increase for UGT2B7-dependent epirubicin The bottom and top of the boxes represent the 25 th and 75 th percentiles, respectively. The solid horizontal line within each box represents the median value. The horizontal dash within each box represents the mean value. The lower whisker is equal to the maximum of 1) lower quartile minus 1.5 times the interquartile range (IQR) and 2) the minimum observation within the IQR. The upper whisker is equal to the minimum of 1) the 75 th percentile plus 1.5 times the IQR and 2) the maximum observation within the IQR.
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Discussion
The use of the anthracycline, doxorubicin, as a chemotherapeutic agent in children has generated considerable concern regarding longterm safety. The development of the less toxic anthracycline derivative, epirubicin, has resulted in a more widespread use of this class of agents for childhood cancer. However, a careful comparison between doxorubicin and epirubicin pharmacokinetics and pharmacodynamics suggests the decreased toxicity of the latter is due to its metabolism and clearance by UGT2B7. Thus, an assessment of the postnatal developmental expression pattern of human hepatic UGT2B7 and, more specifically, the possible changes in activity toward epirubicin, was considered important in the assessment of age-dependent pharmacokinetic changes and variability of this drug in the pediatric population.
The kinetic constants determined in the current study (K m,app ϭ 213 M and V max ϭ 3.56 nmol/min/mg for pooled microsomes; K m ϭ 46 M and V max ϭ 0.86 nmol/min/mg for expressed recombinant protein) are different from those previously reported (K m values of 568 M and 149 M for human liver microsomes and expressed UGT2B7, respectively). These comparatively higher affinity constants may be attributable to the higher microsomal protein concentration used by these investigators (3 mg/ml microsomal protein).
Although not measured experimentally in the current study, nonspecific microsomal protein binding is well documented for producing increased relative affinity parameters for in vitro studies (Obach, 1999; Kalvass et al., 2001) . The 4-fold difference in apparent K m values between human liver microsomes and the expressed microsomal UGT2B7 enzyme has been noted previously and may be attributable to 1) the involvement of an unidentified higher-affinity human liver UGT form in the glucuronidation of epirubicin, 2) the influence of incubation conditions or the lipid environment of the microsomal preparations (Remmel and Burchell, 1993; Fisher et al., 2000; Soars et al., 2003) , or 3) alteration of UGT kinetics and activity due to oligomerization (Ikushiro et al., 1997; Meech and Mackenzie, 1997; Ishii et al., 2001 ). An examination of epirubicin glucuronidation activity in pediatric liver microsomes demonstrated a median activity in tissue from individuals less than 1 year of age that was approximately 10% of that observed in tissue from adults. Between 1 year of age and puberty (11 years of age), median enzyme activity was 25% of that seen in adults, whereas between 12 and 17 years of age, the observed median activity was approximately 50% of the observed adult value. These relative values are corroborated by the immunological determination of UGT2B7 content, which correlated well with enzyme activity (r ϭ 0.86). However, if one normalizes the pediatric data to a 70-kg individual using the 3 ⁄4 power rule, no significant differences are observed among the different developmental age groups or between any of the pediatric age groups and adults (Table 3 ) ( p ϭ 0.138). These data are consistent with morphine clearance in pediatric patients by glucuronidation, a well documented marker of UGT2B7 activity (Coffman et al., 1997) . Morphine clearance was 5-fold higher in children 1 to 16 years of age versus neonates, but clearance values matching adults were attained between 6 and 30 months when calculated using a per-kg size model (Choonara et al., 1989) . When scaled using the 3 ⁄4 power model, adult levels of morphine clearance were attained between 2 and 6 months of age (Anderson et al., 1997 ). In the current data set, only one of the tissue samples analyzed was from a FIG. 3 . Immunoblot analysis of UGT2B7 protein in human liver microsomes. Lanes 1 to 6 contain 0.005, 0.01, 0.025, 0.050, 0.10, and 0.25 g, respectively, of expressed UGT2B7. Lane 7 contains UGT insect control microsomal protein, and lanes 8 to 15 include samples from the Ͻ1-year postnatal age group (3 g of total protein per analysis). Lane 16 contains pooled human liver microsomes (3 g). Electrophoresis and immunodetection using an antibody to UGT2B7 were conducted as described under Materials and Methods.
FIG. 4.
Box and whisker plot analysis of immunodetectable UGT2B7 determined for pediatric and adult liver microsomal samples. Protein levels (g expressed UGT2B7/mg microsomal protein) were quantitated as described under Materials and Methods. The bottom and top of the boxes represent the 25 th and 75 th percentiles, respectively. The solid horizontal line within each box represents the median value. The horizontal dash within each box represents the mean value. The lower whisker is equal to the maximum of 1) lower quartile minus 1.5 times the IQR and 2) the minimum observation within the IQR. The upper whisker is equal to the minimum of 1) the 75 th percentile plus 1.5 times the IQR and 2) the maximum observation within the IQR. at ASPET Journals on July 7, 2017 dmd.aspetjournals.org neonate, only two were from individuals less than 2 months of age, and the median age of all samples less than 1 year of age was 4.8 months.
In summary, epirubicin glucuronidation activity and content clearly vary directly as a function of increasing age. However, when pediatric data were normalized using 3 ⁄4 power allometric scaling, epirubicin glucuronidation activity in all pediatric age categories was not found to be statistically different from activities determined for the adult liver samples. These data are consistent with data on the ontogeny of morphine glucuronidation wherein adult activity values are attained by 2 to 6 months of age. Thus, the data presented in the current study would support the use of epirubicin as a cancer chemotherapeutic agent in pediatric patients older than 6 months of age. FIG. 6 . Correlation between epirubicin glucuronidation activity and UGT2B7 content and postnatal age. A, correlation between epirubicin glucuronidation activity and postnatal age (PNA) in pediatric liver microsomes (n ϭ 32). Coefficient of determination (r 2 ) ϭ 0.13. The correlation coefficient (r) ϭ 0.36, p ϭ 0.047. B, correlation between UGT2B7 content and PNA in pediatric liver microsomes (n ϭ 32). Coefficient of determination (r 2 ) ϭ 0.47. The correlation coefficient (r) ϭ 0.68, p Ͻ 0.0001. a Individual pediatric activities were scaled and normalized to a 70-kg individual using the 3/4 power allometric rule (Activity 70kg ϭ Activity i /(Weight i /70 kg) 0.75 , where Activity i and Weight i are the activity and weight of the individual pediatric samples, respectively).
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